Encouraging survival data for new melanoma drugs
Concurrent treatment with nivolumab and ipilimumab for patients with advanced melanoma results in overall survival of 82% and 75% at one year and two years, respectively, reveals follow-up of a phase Ib study.
Median life expectancy for patients with advanced disease is usually six to nine months and the survival results were described as “encouraging” by the researchers, who presented the results at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday.
Nivolumab is a new monoclonal antibody which helps the body’s immune system recognise cancer cells; it is still undergoing clinical trials. Ipilimumab is licensed for previously treated advanced melanoma and marketed as Yervoy.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138889
Recommended from Pharmaceutical Press